Agreement to enable the first entry in Latin America for Bavarian Nordic’s chikungunya vaccine ...

EINDHOVEN, the Netherlands, Jan. 23, 2026 (GLOBE NEWSWIRE) -- ONWARD Medical N.V. (Euronext: ONWD – US ADR: ONWRY), the neurotechnology company pioneering spinal cord stimulation therapies to restore ...

SHORE study In the SHORE study, amlitelimab, dosed either Q4W or Q12W in conjunction with medium-potency background topical corticosteroids (TCS) with or without topical calcineurin inhibitors (TCI), ...

Adaptive Biotechnologies (“we” or “our”) is a commercial-stage biotechnology company focused on harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment ...

The Medtronic investment and the underwritten public offering of common stock position Anteris to continue to execute the global PARADIGM Trial and to continue investing in research that can transform ...

D Path, a company dedicated to personalizing cancer care through a novel, physics-inspired approach to predicting tumor response to therapy, today announced its participation as an exploratory ...

River Oaks Treatment Center, traditionally recognized for its expertise in treating substance use and co-occurring disorders, has recently broadened its mission to include specialized mental health ...

NEW YORK, Jan. 22, 2026 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“ Psyence BioMed ” or the “ Company ”) today announced that it adjourned its annual and special meeting of ...

Fourth quarter and full year 2025 investor conference call scheduled for February 25, 2026 at 4:30 p.m. ET Arcutis management to present at the Guggenheim Emerging Outlook: Biotech Summit on February ...

New Westminster, BC, Jan. 22, 2026 (GLOBE NEWSWIRE) -- LifeLabs, Canada's leading provider of medical diagnostic services, has officially opened a new Patient Service Centre (PSC) in Uptown New ...

Kaida BioPharma (“Kaida” or the “Company”), a biopharmaceutical company focused on advancing targeted anti-cancer therapies for hormone-driven cancers affecting women, today announced a leadership ...

The study will be conducted in three phases. Part A is a Phase 2, open-label, semi-sequential dose-ranging portion of the study. Part B is the Phase 3, double-blind, randomized, placebo controlled ...